文献速递免疫规划卫生政策与健康促进

RTS,S/AS01疟疾疫苗的季节性使用案例:一项数学建模研究

Seasonal use case for the RTS,S/AS01 malaria vaccine: a mathematical modelling study.
PubMed 文献 · Lancet Glob Health · 2022-01-01

基于个体数学传播模型,评估季节性接种RTS,S/AS01疟疾疫苗在非洲季节性传播地区的效果。

要点

  • 季节性接种RTS,S较按年龄接种可额外避免更多疟疾病例和死亡。
  • 在SMC基础上加用季节性RTS,S较单用SMC可进一步降低临床发病率。
  • 传播季节时长是干预效果的关键决定因素,季节越短加用RTS,S的优势越小。

核心结论

  • 在季节性传播地区,RTS,S接种可作为现有干预措施的有价值补充工具,季节性接种较按年龄接种能最大化效果。
  • RTS,S在此类地区的部署策略需考虑当地和区域季节性的差异、其他干预措施的当前覆盖率以及可实现的RTS,S覆盖率。

研究设计与样本

  • 研究使用基于个体的疟疾传播数学模型,模型拟合了非洲多个地点的昆虫学接种率与寄生虫患病率、临床疾病、严重疾病和死亡之间的关系数据。
  • 模型通过在马里和布基纳法索评估SV-RTS,S效果的3b期试验结果进行了验证。
  • 研究开发了三个具有不同保护程度和保护持续时间的干预效力模型,用于人群水平建模分析。
  • 评估了基于年龄的RTS,S接种方案(前三次剂量在6月龄、7.5月龄和9月龄接种,第四剂在27月龄接种)和季节性接种方案(5-17月龄儿童在传播季节前3个月内接种前三次剂量,后续每年最多接种五剂)在季节性传播地区的效果,分别在有和无SMC(磺胺多辛-乙胺嘧啶加阿莫地喹,在传播高峰季节每月全疗程给药,持续四或五个月)的条件下进行。
  • 在100 000名0-5岁儿童人群中,计算了15年时间内不同疟疾传播强度水平(2-10岁儿童恶性疟原虫 parasite prevalence 在10%至65%之间)和两种西非季节性原型下的病例和死亡避免估计值。

主要发现

  • 与基于年龄的策略相比,季节性靶向RTS,S在疟疾病例和死亡方面带来更大的绝对减少,在15年内每100 000名5岁及以下儿童中额外避免14 000-47 000例病例,具体取决于季节性和传播强度。
  • 预测在SMC基础上加用季节性靶向RTS,S,与单用SMC相比,在15年内每100 000名5岁及以下儿童中临床发病率可额外减少多达42 000-67 000例。
  • 传播季节时长是干预效果的关键决定因素,传播季节越短,加用RTS,S于SMC的预测优势越小。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A 2021 clinical trial of seasonal RTS,S/AS01E (RTS,S) vaccination showed that vaccination was non-inferior to seasonal malaria chemoprevention (SMC) in preventing clinical malaria. The combination of these two interventions provided significant additional protection against clinical and severe malaria outcomes. Projections of the effect of this novel approach to RTS,S vaccination in seasonal transmission settings for extended timeframes and across a range of epidemiological settings are needed to inform policy recommendations. METHODS: We used a mathematical, individual-based model of malaria transmission that was fitted to data on the relationship between entomological inoculation rate and parasite prevalence, clinical disease, severe disease, and deaths from multiple sites across Africa. The model was validated with results from a phase 3b trial assessing the effect of SV-RTS,S in Mali and Burkina Faso. We developed three intervention efficacy models with varying degrees and durations of protection for our population-level modelling analysis to assess the potential effect of an RTS,S vaccination schedule based on age (doses were delivered to children aged 6 months, 7·5 months, and 9 months for the first three doses, and at 27 months of age for the fourth dose) or season (children aged 5-17 months at the time of first vaccination received the first three doses in the 3 months preceding the transmission season, with any subsequent doses up to five doses delivered annually) in seasonal transmission settings both in the absence and presence of SMC with sulfadoxine-pyrimethamine plus amodiaquine. This is modelled as a full therapeutic course delivered every month for four or five months of the peak in transmission season. Estimates of cases and deaths averted in a population of 100 000 children aged 0-5 years were calculated over a 15-year time period for a range of levels of malaria transmission intensity (Plasmodium falciparum parasite prevalence in children aged 2-10 years between 10% and 65%) and over two west Africa seasonality archetypes. FINDINGS: Seasonally targeting RTS,S resulted in greater absolute reductions in malaria cases and deaths compared with an age-based strategy, averting an additional 14 000-47 000 cases per 100 000 children aged 5 years and younger over 15 years, dependent on seasonality and transmission intensity. We predicted that adding seasonally targeted RTS,S to SMC would reduce clinical incidence by up to an additional 42 000-67 000 cases per 100 000 children aged 5 years and younger over 15 years compared with SMC alone. Transmission season duration was a key determinant of intervention effect, with the advantage of adding RTS,S to SMC predicted to be smaller with shorter transmission seasons. INTERPRETATION: RTS,S vaccination in seasonal settings could be a valuable additional tool to existing interventions, with seasonal delivery maximising the effect relative to an age-based approach. Decisions surrounding deployment strategies of RTS,S in such settings will need to consider the local and regional variations in seasonality, current rates of other interventions, and potential achievable RTS,S coverage. FUNDING: UK Medical Research Council, UK Foreign Commonwealth & Development Office, The Wellcome Trust, and The Royal society.

来源:Lancet Glob Health,查看原文。版权归原作者所有。

引用

  1. Thompson HA, Hogan AB, Walker PGT, et al. Seasonal use case for the RTS,S/AS01 malaria vaccine: a mathematical modelling study. Lancet Glob Health. 2022. PMID: 36400084. doi:10.1016/S2214-109X(22)00416-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。